Login or sign up Lost password?
Login or sign up
The numbers of all Grade and Grade 3-4 toxicities were 86.9% and 18% in the combined-treatment group versus 77.8% and 9.5% with nivolumab alone." data-reactid="31" am Bristol-Myers presents results from the IFCT-1501 MAPS-2 trial evaluating the safety and efficacy of nivolumab or nivolumab combined with ipilimumab for previously treated unresectable malignant pleural mesothelioma patients at 2017 ASCO (BMY) : The 12-week disease control rate, the primary endpoint of the study, was 44.4% [95% CI: 31.2-57.7%] with nivolumab, and 50% [36.7-63.3%] with nivolumab plus ipilimumab, as assessed by an independent panel of radiologists.